UK National Registry of Rare Kidney Disease: Long-Term Outcomes in the IgA Nephropathy Cohort
FILSPARI (sparsentan) – Safety Data Sheet
Impact of Proteinuria and Kidney Function Decline on Health Care Costs and Resource Utilization in Adults With IgA Nephropathy in the United States: A Retrospective Analysis
Long-Term Outcomes in IgA Nephropathy
Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis
FILSPARI (sparsentan) – Baseline Characteristics of Asian vs Non-Asian Patients in the PROTECT Study
Sparsentan in Patients With IgA Nephropathy: A Prespecified Interim Analysis From a Randomised, Double-Blind, Active-Controlled Clinical Trial
FILSPARI (sparsentan) – Hyperkalemia
Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: An Open-Label Drug–Drug Interaction Study in Healthy Adults
FILSPARI (sparsentan) – Acute Kidney Injury
FILSPARI (sparsentan) – Impact on Pregnancy, Lactation, and Fertility
FILSPARI (sparsentan) Dual Receptor Antagonism in Renal Pathophysiology and Reduction of Proteinuria
FILSPARI (sparsentan) – Effect on Estimated Glomerular Filtration Rate (eGFR) in IgA Nephropathy